Effects of long-term growth hormone replacement in adults with growth hormone deficiency following cure of acromegaly: A KIMS analysis

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 6, 2014, Pages 2018-2029

  Tritos, Nicholas A ^a   Johannsson, Gudmundur ^b   Korbonits, Márta ^d   Miller, Karen K ^a   Feldt Rasmussen, Ulla ^e   Yuen, Kevin C J ^f   King, Donna ^g   Mattsson, Anders F ^c   Jonsson, Peter J ^g   Koltowska Haggstrom, Maria ^g   Klibanski, Anne ^a   Biller, Beverly M K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Department of Endocrinology ^*  (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e Rigshospitalet   (Denmark)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACROMEGALY; ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR MORTALITY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NONFUNCTIONING PITUITARY ADENOMA; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; THERAPY EFFECT;

ACROMEGALY; ADULT; AGED; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902312421     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-1013     Document Type: Article

References (54)

1. Clemmons DR. The diagnosis and treatment of growth hormone deficiency in adults. Curr Opin Endocrinol Diabetes Obes. 2010; 17:377-383.
2. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone d eficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1587-1609.
3. Ronchi CL, Giavoli C, Ferrante E, et al. Prevalence ofGHdeficiency in cured acromegalic patients: impact of different previous treatments. Eur J Endocrinol. 2009;161:37-42.
4. van der Klaauw AA, Bax JJ, Bleeker GB, et al. Cardiac manifestations ofGHdeficiency after treatment for a cromegaly: a comparison to patients with biochemical remission and controls. Eur J Endocrinol. 2008;159:705-712.
5. Wexler T, Gunnell L, Omer Z, et al. Growth hormone deficiency is associated wit h decreased quality of life in patients with prior acromegaly. J Clin Endocrinol Metab. 2009;94:2471-2477.
6. Lin E, Wexler TL, Nachtigall L, et al. Effects of growth hormone deficiency on body c omposition and biomarkers of cardiovascular risk after definitive therapy for acromegaly. Clin Endocrinol (Oxf). 2012;77:430-438.
7. Miller KK, Wexler T, Fazeli P, et al. Growth hormone deficien cy after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement. J Clin Endocrinol Metab. 2010;95:567-577.
8. Valassi E, Brick DJ, Johnson JC, Biller BM, Klibanski A, Miller KK. Effect of growth hormone replacement therapy on the quality of life in women with growth hormone deficiency who have a history of acromegaly ver sus other disorders. Endocr Pract. 2012;18:209-218.
9. Giavoli C, Profka E, Verrua E, et al. GH replacement improves quality of life and metabolic parameters in cured acromegalic patients with g rowth hormone deficiency. J Clin Endocrinol Metab. 2012;97:3983-3988.
10. Norrman LL, Johannsson G, Sunnerhagen KS, Svensson J. Baseline characteristics and the effects of two years of growth ho rmone (GH) replacement therapy in adults withGHdeficiency previously treated for acromegaly. J Clin Endocrinol Metab. 2008;93:2531-2538.
11. Feldt-Rasmussen U, Abs R, Bengtsson BA, et al. Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing's disease. Eur J Endocrinol. 2002;146:67-74.
12. van der Klaauw AA, Bax JJ, Roelfsema F, et al. Limited effects of growth hormone replacement in patients withGHdeficiency during long-term cure of acromegaly. Pituitary. 2009;12:339-346.
13. Tritos NA, Greenspan SL, King D, et al. Unreplaced sex steroid deficiency, corticotropin deficiency, and lower IGF-I are associated with lower bone mineral density in adults with growth hormone deficiency: a KIMS database a nalysis. J Clin Endocrinol Metab. 2011;96:1516-1523.
14. Ho KK. Consensus guidelines for the diagnosis and treatment of adults withGHdeficiency II: a statement of theGHResearch Society in association with t he European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol. 2007;157:695-700.
15. Rii s P. Thirty years of bioethics: the Helsinki Declaration 1964-2003. New Rev Bioeth. 2003;1:15-25.
16. McKenna SP, Doward LC, Alonso J, et al. The QoL-AGHDA: an instrument for the asses sment of quality of life in adults with growth hormone deficiency. Qual Life Res. 1999;8:373-383.
17. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(Suppl 1):S62-S69.
18. Luger A, Mattsson AF, Koltowska-Häggström M, et al. Incidence of diabetes mellitus and evolution of glucose parameters in growth hormone-deficient subjects during growth h ormone replacement therapy: a long-term observational study. Diabetes Care. 2012;35: 57-62.
19. Mathers CD, Bernard C, Moesgaard Iburg K, et al. Global burden of disease in 2002: data sources, methods and results. In: Global Programme on Evidence for Health Policy. World Health Organization; 2003:1-113.
20. Curado MP, Edwards B, Shin HR, et al. Cancer Incidence in Five Continents. Lyon, France: IARC Scientific Publications No 160; 2007.
21. Thunander M, Petersson C, Jonzon K, et al. Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden. Diabetes Res Clin Pract. 2008;82:247-255.
22. Bonora E Kiechl S Willeit J et al Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study Diabetes. 2004 53 1782-1789.
23. Geiss LS, Pan L, Cadwell B, Gregg EW, Benjamin SM, Engelgau MM. Changes in incidence of diabetes in U.S. adults, 1997-2003. Am J Prev Med. 2006;30:371-377.
24. Meisinger C, Thorand B, Schneider A, Stieber J, Döring A, Lö wel H. Sex differences in risk factors for incident type 2 diabetes mellitus: the MONICA Augsburg cohort study. Arch Intern Med. 2002;162: 82-89.
25. Rathmann W, Strassburger K, Heier M, et al. Incidence of type 2 diabetes in the elderly German population and the effect of clinical and lifestyle risk factors: KORA S4/F4 cohort study. Diabet Med. 2009;26:1212-1219.
26. Tritos NA, Hamrahian AH, King D, et al. Predictors of the effects of 4 years of growth hormone replacement on bone mineral density in patients with adult-onset growth hormone deficiency-A KIMS databas e analysis. Clin Endocrinol (Oxf). 2013;79:178-184.
27. Brabant G, von zur Mü hlen A, Wüster C, et al. Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay syste m: results from a multicenter study. Horm Res. 2003;60:53-60.
28. Breslow D. The design and analysis of cohort studies. In: Statistical Methods in Cancer Research. Lyon, France: IARC Scientific Publications; 1987:69.
29. Biermasz NR, van Dulken H, Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab. 2000;85:2476-2482.
30. Murray RD, Peacey SR, Rahim A, Toogood AA, Thorner MO, Shalet SM. The diagnosis of growth hormone deficiency (GHD) in successfully treated acromegalic patients. Clin Endocrinol (Oxf). 2001;54:37-44.
31. Fujio S, Tokimura H, Hirano H, et al. Severe growth hormone deficiency is rare in surgically-cured acromegalics. Pituitary. 2013;16: 326-332.
32. Koitowska-Haggstrom M, Hennessy S, Mattsson AF, Monson JP, Kind P. Quality of life assessment of growth hormone deficiency in adults (QoL-AGHDA): comparison of normative reference data for the general population of England and Wales with results for adult hypopituitary p atients with growth hormone deficiency. Horm Res. 2005;64:46-54.
33. Koltowska-Hä ggström M, Mattsson AF, Monson JP, et al. Does long-termGHreplacement therapy in hypopituitary adults withGH deficiency normalise quality of life? Eur J Endocrinol. 2006;155: 109-119.
34. Bjö rk S, Jönsson B, Westphal O, Levin JE. Quality of life of adults with growth hormone deficiency: a controlled study. Acta Pa ediatr Scand Suppl. 1989;356:55-59; discussion 60, 73-74.
35. Burman P, Broman JE, Hetta J, et al. Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant humanGHin a placebo-controlled 21-month trial. J Clin Endocrinol Metab. 1995;80:3585-3590.
36. Attanasio AF, Shavrikova EP, Blum WF, Shalet SM. Quality of life in childhood onset growth hormone-deficient patients in the transition phase from childhood to adulthood. J Clin Endocrinol Metab. 2005;90:4525-4529.
37. Baum HB, Katznelson L, Sherman JC, et al. Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficiency. J Clin Endocrinol Metab. 1998;83:3184-3189.
38. Monson JP, Jonsson P, Koltowska-Haggstrom M, Kourides I. Growth hormone (GH) replacement decreases serum total andLDLcholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapy. Clin Endocrinol (Oxf). 2007; 67:623-628.
39. Abrams P, Boquete H, Fideleff H, et al. GH replacement in hypopituitarism improves lipid profile and quality of lif e independently of changes in obesity variables. Eur J Endocrinol. 2008;159:825-832.
40. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P. Impact of growth hormone (GH) trea tment on cardiovascular risk factors in GH-deficient adults: a meta-analysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab. 2004; 89:2192-2199.
41. Weaver JU, Monson JP, Noona n K, et al. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab. 1995;80:153-159.
42. Sherlock M, Ayuk J, Tomlinson JW, et al. Mortality in patients with pituitary disease. Endocr Rev. 2010;31:301-342.
43. Gaillard RC Mattsson AF Akerblad AC et al Overall and causespecific mortality in GH-deficient adults on GH replacement Eur J Endocrinol. 2012 166 1069-1077.
44. Nielsen EH, Lindholm J, Laurberg P. Excess mortality in women with pituitary disease: a meta-analysis. Clin Endocrinol (Oxf). 2007;67:693-697.
45. Erfurth EM. Update in mortality in GH-treated patients. J Clin Endocrinol Metab. 2013;98:4219-4226.
46. Annamalai AK, Webb A, Kandasamy N, et al. A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing p resurgical somatostatin receptor ligand therapy. J Clin Endocrinol Metab. 2013;98:1040-1050.
47. Espinosa-de-los-Monteros AL, González B, Vargas G, Sosa E, Mercado M. Clinical and biochemica l characteristics of acromegalic patients with different abnormalities in glucose metabolism. Pituitary. 2011;14:231-235.
48. Jayasena CN, Comninos AN, Clarke H, Donaldson M, Meeran K, Dhillo WS. The effects of long-term growth hormone and insulinlike growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly. Clin Endocrinol (Oxf). 2011;7 5:220-225.
49. Clayton PE, Banerjee I, Murray PG, Renehan AG. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol. 2011;7:11-24.
50. Mackenzie S, Craven T, Gattamaneni HR, Swindell R, Shalet SM, Brabant G. Long-term safety of growth hormone replacement after CNS irradiation. J Clin Endocrinol Metab. 2011;96:2756-2761.
51. Braganza MZ, Kitahara CM, Berrington de González A, Inskip PD, Johnson KJ, Rajaraman P. Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro Oncol. 2012;14:1316-1324.
52. Prasad G, Haas-Kogan DA. Radiation-induced gliomas. Expert Rev Neurother. 2009;9:1511-1517.
53. Attanasio AF, Jung H, Mo D, et al; HypoCCS International Advisory Board. Prevalence and incidence of diabetes mellitus in adult patients on growth hormone replacement for growth hormone deficiency: a surveillance database analysis. J Clin Endocrinol Metab. 2011;96:22 55-2261.
54. Abs R, Mattsson AF, Thunander M, et al. Prevalence of diabetes mellitus in 6050 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis. Eur J Endocrinol. 2013;168:297-305.